{"classes":[{"categories":[{"measurements":[{"comment":"Summary statistics are not presented as geometric means were not calculated if fewer than 3 participants had reportable values.","groupId":"OG003","spread":"NA","value":"NA"},{"groupId":"OG004","spread":"41","value":"47.09"},{"groupId":"OG005","spread":"19","value":"90.35"},{"comment":"Summary statistics are not presented as geometric means were not calculated if fewer than 3 participants had reportable values.","groupId":"OG006","spread":"NA","value":"NA"},{"comment":"Summary statistics are not presented as geometric means were not calculated if fewer than 3 participants had reportable values.","groupId":"OG007","spread":"NA","value":"NA"},{"comment":"Summary statistics are not presented as geometric means were not calculated if fewer than 3 participants had reportable values.","groupId":"OG009","spread":"NA","value":"NA"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"2"},{"groupId":"OG004","value":"3"},{"groupId":"OG005","value":"3"},{"groupId":"OG006","value":"2"},{"groupId":"OG007","value":"2"},{"groupId":"OG008","value":"0"},{"groupId":"OG009","value":"1"}],"units":"Participants"}],"title":"Cycle 1 Day 1"},{"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"0"},{"groupId":"OG009","value":"0"}],"units":"Participants"}],"title":"Cycle 2 Day 1"}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"2"},{"groupId":"OG004","value":"4"},{"groupId":"OG005","value":"5"},{"groupId":"OG006","value":"4"},{"groupId":"OG007","value":"3"},{"groupId":"OG008","value":"2"},{"groupId":"OG009","value":"1"}],"units":"Participants"}],"description":"AUCinf was calculated as AUClast +(Clast\\*/kel), where AUClast is area under the serum concentration-time profile from time 0 to the time of the last quantifiable concentration, Clast\\* is the predicted serum concentration at the last quantifiable time point estimated from the log-linear regression analysis, kel is the terminal phase rate constant calculated by a linear regression of the log-linear concentration-time curve. Only those data points judged to describe the terminal log-linear decline were used in the regression.\n\nGeometric mean was not calculated if fewer than 3 participants had reportable parameter values.","dispersionType":"Geometric Coefficient of Variation","groups":[{"description":"PF-06671008 was administered as a weekly intravenous (IV) infusion in 21-day cycles at 1.5 ng/kg. PF-06671008 was administered for up to 4 cycles in this cohort.","id":"OG000","title":"PF-06671008 1.5 ng/kg IV"},{"description":"PF-06671008 was administered as a weekly IV infusion in 21-day cycles at 7.5 ng/kg. PF-06671008 was administered for up to 3 cycles in this cohort.","id":"OG001","title":"PF-06671008 7.5 ng/kg IV"},{"description":"PF-06671008 was administered as a weekly IV infusion in 21-day cycles at 20 ng/kg. PF-06671008 was administered for up to 4 cycles in this cohort.","id":"OG002","title":"PF-06671008 20 ng/kg IV"},{"description":"PF-06671008 was administered as a weekly IV infusion in 21-day cycles at 50 ng/kg. PF-06671008 was administered for up to 2 cycles in this cohort.","id":"OG003","title":"PF-06671008 50 ng/kg IV"},{"description":"PF-06671008 was administered as a weekly IV infusion in 21-day cycles at 100 ng/kg. PF-06671008 was administered for up to 4 cycles in this cohort.","id":"OG004","title":"PF-06671008 100 ng/kg IV"},{"description":"PF-06671008 was administered as a weekly IV infusion in 21-day cycles at 200 ng/kg. PF-06671008 was administered for up to 16 cycles in this cohort.","id":"OG005","title":"PF-06671008 200 ng/kg IV"},{"description":"PF-06671008 was administered as a weekly IV infusion in 21-day cycles at 300 ng/kg. PF-06671008 was administered for up to 4 cycles in this cohort.","id":"OG006","title":"PF-06671008 300 ng/kg IV"},{"description":"PF-06671008 was administered as a weekly IV infusion in 21-day cycles at 400 ng/kg. PF-06671008 was administered for up to 2 cycles in this cohort.","id":"OG007","title":"PF-06671008 400 ng/kg IV"},{"description":"PF-06671008 was administered as a weekly subcutaneous (SC) injection in 21-day cycles at 200 ng/kg. PF-06671008 was administered for up to 5 cycles in this cohort.","id":"OG008","title":"PF-06671008 200 ng/kg SC"},{"description":"PF-06671008 was administered as a weekly IV infusion in 21-day cycles at a priming dose of 200 ng/kg on Cycle 1 Day 1 (C1D1) and 300 ng/kg for all subsequent dosing. PF-06671008 was administered for up to 4 cycles in this cohort.","id":"OG009","title":"PF-06671008 200 ng/kg Prime and 300 ng/kg Maintenance IV"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"All enrolled participants treated who had sufficient information to estimate at least 1 of the PK parameters of interest and who had no major protocol deviations influencing the PK assessment.","reportingStatus":"POSTED","timeFrame":"C1D1 0, 1, 2, 4, 8, 24, 48, 72 and 96 hrs post-dose, C2D1 0, 2, 4, 8, 24, 48, 72 and 96 hrs post-dose","title":"Area Under the Curve From Time 0 Extrapolated to Infinity Time (AUCinf) of PF-06671008","type":"SECONDARY","unitOfMeasure":"ng.hr/mL"}